In fact, there are many raw material pharmaceutical companies in China now. It is no exaggeration to say that we are the world's number one raw material pharmaceutical producer.

But why can we produce the most raw materials, but not when producing high-end finished products?

For example, the most commonly used broad-spectrum antibiotic penicillin on the market, this drug has a history of hundreds of years since its discovery.

It still plays a very wide role in the medical community. This antibiotic can not only be used as an anti-inflammatory and sterilization drug, but also as a basic raw material for many other drugs.

But even such a common drug with a wide range of uses, we still need to import large quantities from abroad in China.

The main import target is Roche, Switzerland.

Why? It’s because we can’t do it well!

Although they are all penicillin, they are just oral.

Our products take longer than others when they are absorbed by the human body and enter the blood circulation.

Other people's drugs can reach concentration peaks in the blood more quickly, and the time it exists in the blood, which is commonly understood as the duration of the drug, is longer than ours.

In this way, the effect of others will naturally be better.

According to comparison and analysis, the efficacy of penicillin we produce is basically about 80% of Roche.

Moreover, even if the price of penicillin is shipped to the port, it is not much more expensive than ours.

So who do you think the pharmaceutical factory will purchase?

And Roche's penicillin is so good.

The main thing is that it has its own unique secrets in terms of process processes.

Many drugs, although the patent protection period has passed, many pharmaceutical manufacturers can copy them.

But although you know other people's molecular formulas and synthesis methods, you may not be able to make medicines with the same effect as others.

Because the reverse development of drugs is not as simple as everyone imagines, and the difficulty is very high.

Because many pharmaceutical factories have their own unique processes and processes, and it is these that determine the effectiveness of the drug.

In order to make the drug work best, many of its production equipment are specially designed.

And you will never know this if you don’t go deep into it, or if you don’t see it in someone else’s factory.

This is also the main reason why the generic drugs in India are so awesome.

At present, several Indian pharmaceutical companies can do the same in the world that can achieve the effect of the drug by fake or even restore the original drug almost 100%.

Even if the technology is as strong as Japan, it cannot achieve the imitation capabilities of Indian pharmaceutical companies.

What Xiao Feng needs to do now is to learn from India and improve the research and development capabilities of domestic pharmaceutical companies in generic drugs.

To be honest, anyone who knows domestic pharmaceutical companies knows that the positive R&D capabilities of our domestic pharmaceutical companies can be said to be too weak now.

Because in the past few decades, we were just focusing on developing the economy? Everyone was working hard to scale.

The company does not invest much money in R&D, especially pharmaceutical companies? Once they want to engage in R&D, the investment will be too large.

And the R&D cycle is still long? Even if it is developed in the end, it will take a long time of clinical trials before it can be approved.

The cost of conducting clinical trials in China is very high, and there are still many restrictions on all aspects.

Therefore, all domestic pharmaceutical companies do not like to engage in research and development.

This has caused us to owe too much debt? In recent years, the above have also noticed this issue? Therefore, many policies have been introduced to encourage and stimulate pharmaceutical companies to engage in positive research and development.

In recent years, many domestic pharmaceutical companies have increased their investment in this area.

But for the results, it may take several years to wait.

After all, it takes several years to develop medicine? Then it takes several years to develop it.

So the result is not achieved in one or two years.

Now, many of the upstream and downstream enterprises around the Ninth Laboratory are actually small and medium-sized enterprises with low risk resistance.

The industries these small and medium-sized enterprises are engaged in? The technical requirements? The entry threshold is not high? Therefore, the competition is also very fierce.

These small and medium-sized enterprises have very poor risk resistance. Maybe they have lived a very good life after taking the order from the Ninth Laboratory this year.

But if another company snatches the order next year, it will not be able to survive and may go bankrupt.

Originally, how these companies were living was not about the Ninth Laboratory.

But now Xiao Feng and He Xiaojun said that he wants to choose a few ambitious companies in the upstream and downstream industrial chain of the Ninth Laboratory to support it.

The purpose of his founding of the Quanye Fund was actually to build an industrial alliance with the Ninth Laboratory as the core.

After all, no one knows what risks a company will encounter in the future. As the saying goes, one hero and three helpers.

If the Ninth Laboratory encounters any risks in the future, I will take you with me as a little brother who can be a meat shield and charge at any time.

That is much better than relying on yourself and fighting alone.

And sometimes, when something happens, it is not convenient for you to come forward by yourself, but the younger brothers around you can jump out to help you solve it.

This is also one of the main reasons why Xiao Feng wanted to build this alliance.

"Well, I will ask the people below to sort out a detailed list of our upstream and downstream companies."

"I will ask our people to select some companies from it."

He Xiaojun also fully understood Xiao Feng's intention at this time, so he also agreed with this idea.

"Well, remember to let our people have a good chat with the owners of those companies. Remember that we are investing in people, not their companies!"

Xiao Feng knocked on the table and said the point, and He Xiaojun nodded. He understood Xiao Feng's meaning very well.

The companies they want to support are definitely not those with light surfaces of donkey dung eggs.

The companies they want to support are those with ambitious owners.

It is the kind of owner who is absolutely unwilling to give up and only makes medicine packaging for the ninth laboratory or supplies raw materials.

It is the kind of entrepreneur who makes money and wants to enter an owner with a technical moat industry and is motivated.

After all, in this impetuous era, we need this kind of business owner who is willing to work in business, can endure loneliness, temptation, and is willing to work hard on one acre of land.

After working in the industry for so many years, Xiao Feng believes that only such owners can become great in the future.

To be honest, although many people in China are saying that industry is difficult, there are still many bosses who insist on doing business.

But many of these bosses are eliminated by the industry every year.

Many bosses also feel very confused, why is it so difficult to do business now?

Because our current situation is that we have entered the stage of the trap of middle-class countries.

In the past, we were all working in the simplest primary processing industries, which mainly rely on labor, that is, labor-intensive industries with high pollution.

Because such industries have low entry thresholds, once they see money making, they are prone to fighting and rushing.

The final outcome is that business owners of various businesses have snatched prices from each other, keeping profits very low, and finally letting foreign buyers get the bargain for nothing.

Now many entrepreneurs have understood this point, and they don’t seem to be working on the hardest bottom of the industrial chain, and they all want to reach the peak.

But the upstream of the industrial chain has always been a high-profit area controlled by developed countries in Europe, America, Japan and South Korea. How could this area be so easy to make breakthroughs?

Therefore, many entrepreneurs today will lament that the industry is too difficult to do now.

If the small and medium-sized enterprises around the Ninth Laboratory are asked to directly make original medicines as soon as they come up, they would be asking them to commit suicide.

This is very unrealistic, so Xiao Feng’s idea is to let them start from generic drugs.

After all, the patents of generic drugs are basically public now, and the difference between everyone is the process and process.

In this regard, it is not difficult for the cloning experts in the Ninth Laboratory.

For the ninth laboratory, they are disdainful to do generic drugs, after all, they are now the world's first-tier pharmaceutical companies.

If you go to make generic drugs, it will reduce your value by itself.

But the market for generic drugs is not small at all. Xiao Feng does not want to see foreign pharmaceutical companies relying on generic drugs to conquer cities and territory in our domestic market.

Moreover, Mr. Wan’s Penglai Pavilion APP is becoming more and more popular, and now it has become the most popular APP for seeking medical treatment and medicine in China.

The Neptune chain pharmacy of Wan Gongzi’s family has been developing quietly for more than a year.

Regarding this Aquaman Pharmacy, their family has developed extremely low-key, although it has expanded rapidly across the country over the past year.

But I have never advertised any advertisements, but almost all the drug purchase pharmacies recommended by doctors on the Penglai Pavilion APP are this one.

So this pharmacy has now become a hot commodity in the eyes of all pharmaceutical companies.

Just like ordinary large shopping supermarkets, almost all pharmaceutical factories now want to put their own medicine on their shelves.

Therefore, this Aquaman chain pharmacy has now become a trend of becoming the number one chain pharmacy in China.

So if the upstream and downstream companies supported by the Ninth Laboratory really turn generic drugs into it, then sales channels will definitely not be a problem.

Xiao Feng has already thought about everything for those bosses.
Chapter completed!